This company listing is no longer active
Biohaven Pharmaceutical Holding Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Información clave
-37.1%
Tasa de crecimiento de los beneficios
-20.8%
Tasa de crecimiento del BPA
| Crecimiento de la industria Biotechs | -14.6% |
| Tasa de crecimiento de los ingresos | 91.1% |
| Rentabilidad financiera | n/a |
| Margen neto | -118.8% |
| Última actualización de beneficios | 30 Jun 2022 |
Actualizaciones de resultados anteriores recientes
Recent updates
Desglose de ingresos y gastosBeta
Cómo gana y gasta dinero Biohaven Pharmaceutical Holding. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Jun 22 | 860 | -1,021 | 862 | 361 |
| 31 Mar 22 | 738 | -791 | 781 | 361 |
| 31 Dec 21 | 463 | -847 | 714 | 361 |
| 30 Sep 21 | 308 | -865 | 616 | 155 |
| 30 Jun 21 | 190 | -889 | 572 | 131 |
| 31 Mar 21 | 106 | -859 | 526 | 173 |
| 31 Dec 20 | 64 | -767 | 462 | 229 |
| 30 Sep 20 | 29 | -698 | 409 | 222 |
| 30 Jun 20 | 11 | -609 | 318 | 226 |
| 31 Mar 20 | 1 | -639 | 217 | 360 |
| 31 Dec 19 | 0 | -529 | 134 | 345 |
| 30 Sep 19 | 0 | -434 | 76 | 317 |
| 30 Jun 19 | 0 | -390 | 54 | 302 |
| 31 Mar 19 | 0 | -218 | 40 | 155 |
| 31 Dec 18 | 0 | -241 | 35 | 190 |
| 30 Sep 18 | 0 | -213 | 30 | 175 |
| 30 Jun 18 | 0 | -195 | 27 | 162 |
| 31 Mar 18 | 0 | -202 | 22 | 154 |
| 31 Dec 17 | 0 | -139 | 18 | 89 |
| 30 Sep 17 | 0 | -138 | 15 | 87 |
| 30 Jun 17 | 0 | -123 | 11 | 79 |
| 31 Mar 17 | 0 | -83 | 8 | 64 |
| 31 Dec 16 | 0 | -64 | 5 | 56 |
| 30 Sep 16 | 0 | -42 | 4 | 38 |
Ingresos de calidad: 2VN is currently unprofitable.
Margen de beneficios creciente: 2VN is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: 2VN is unprofitable, and losses have increased over the past 5 years at a rate of 37.1% per year.
Acelerando crecimiento: Unable to compare 2VN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: 2VN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-16.7%).
Rentabilidad financiera
Alta ROE: 2VN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.